Kuros Biosciences

𝗧𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗶𝗻𝗱𝗲𝗽𝗲𝗻𝗱𝗲𝗻𝘁 𝗟𝗲𝘃𝗲𝗹 𝟭 𝗵𝘂𝗺𝗮𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝘁𝘂𝗱𝘆 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝙎𝙥𝙞𝙣𝙚 𝗱𝗲𝗺𝗼𝗻𝘀𝘁𝗿𝗮𝘁𝗲𝘀 𝘁𝗵𝗲 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗯𝗲𝗵𝗶𝗻𝗱 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀™ – and its ability to support you and your patients in challenging PLF* procedures. ¹˒² But did you know that all four MagnetOs formulations are FDA cleared throughout the spine including interbody fusion procedures? †³⁻¹⁰ Visit our Evidence Center to learn more about the details of this Level 1 trial – and what it means for you → https://lnkd.in/e5K7XtsM #KurosBiosciences #MagnetOs #Level1Data #GrowBoneMagnetOs #NeedleGrip

A successful week representing Kuros Biosciences in Switzerland! We had the privilege of participating in two outstanding investor events, Baader Helvea Swiss Equities Conference in Bad Ragaz and Octavian AG Seminar in Davos. A heartfelt thank you to all investors and hosts for the engaging conversations, and to our Kuros team for their work and dedication.   #KurosBiosciences #InvestorRelations #SwissEquities #BaaderHelvea #Octavian

Pictured below is our last in-person onboarding group from 2024, congratulations to all! At Kuros Biosciences, we’re committed to empowering our employees with the knowledge and tools they need to succeed. Here's to a future of growing innovation and collaboration! Interested in growing with us at Kuros Biosciences? Click here for our list of open positions → https://lnkd.in/g2H_HwxX #KurosBiosciences #MagnetOs #GrowBoneMagnetOs #NeedleGrip 

Congratulations to Dr. Hanbing Zhou of Hartford Hospital for completing his 𝗳𝗶𝗿𝘀𝘁 𝗰𝗮𝘀𝗲 𝘂𝘀𝗶𝗻𝗴 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀ᵀᴹ 𝗙𝗹𝗲𝘅 𝗠𝗮𝘁𝗿𝗶𝘅!   Thank you to Dr. Zhou and the dedicated professionals at Hartford Bone and Joint for their continued commitment to advancing positive patient outcomes. Here's to many more cases!    Pictured below is Dr. Hanbing Zhou along with Jason DaCruz PA-C. To learn more about our MagnetOs formulations, click here → https://lnkd.in/e5GvEf5s #GrowBoneMagnetOs #Level1Data #MagnetOs #KurosBiosciences Nick Gambino   𝘔𝘢𝘨𝘯𝘦𝘵𝘖𝘴 𝘍𝘭𝘦𝘹 𝘔𝘢𝘵𝘳𝘪𝘹 𝘪𝘴 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘚 𝘰𝘯𝘭𝘺.

𝗪𝗵𝗲𝗻 𝗶𝘁 𝗰𝗼𝗺𝗲𝘀 𝘁𝗼 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗻𝗴 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀™ 𝗶𝗻 𝗵𝘂𝗺𝗮𝗻𝘀, 𝘄𝗲’𝗿𝗲 𝗱𝗼𝗶𝗻𝗴 𝙟𝙪𝙨𝙩 𝙛𝙞𝙣𝙚. In fact, the latest independent Level 1 human clinical study – 𝗻𝗼𝘄 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝙎𝙥𝙞𝙣𝙚 – used fine-cut CTs for a more reliable fusion assessment. And the comparison between MagnetOs and autograft in challenging PLF* procedures was clear cut: ¹˒² • 𝟳𝟵% 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗣𝗟𝗙 𝗳𝘂𝘀𝗶𝗼𝗻 𝗿𝗮𝘁𝗲 • 𝟰𝟳% 𝗔𝘂𝘁𝗼𝗴𝗿𝗮𝗳𝘁 𝗣𝗟𝗙 𝗳𝘂𝘀𝗶𝗼𝗻 𝗿𝗮𝘁𝗲 Visit our Evidence Center to learn more about the details of this Level 1 trial – and what it means for you → https://lnkd.in/e5K7XtsM #KurosBiosciences #MagnetOs #Level1Data #GrowBoneMagnetOs #NeedleGrip

Kuros Biosciences is pleased to announce an exclusive strategic agreement with the Medtronic spinal division. The five-year sales agency agreement provides Medtronic with exclusivity in certain spine geographies within the U.S. market, underscoring a shared commitment to expanding access to Kuros’ pioneering MagnetOsᵀᴹ bone grafting technology.   Chris Fair, Chief Executive Officer of Kuros Biosciences, commented: “What started as a trial agreement has now evolved into a strategic alliance with Medtronic reflecting an important milestone for Kuros. This agreement will also help us drive the scaling up process, further optimize our operating leverage, and continue our rapid revenue growth both with Medtronic and in our own direct channels. “   To read the full press release, click here → https://lnkd.in/eVtVimGw

We are thrilled to share a recent manuscript from the 𝗞𝘂𝗿𝗼𝘀 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 𝘁𝗲𝗮𝗺 published in the 𝗝𝗼𝘂𝗿𝗻𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗺𝗲𝗿𝗶𝗰𝗮𝗻 𝗔𝗰𝗮𝗱𝗲𝗺𝘆 𝗼𝗳 𝗢𝗿𝘁𝗵𝗼𝗽𝗮𝗲𝗱𝗶𝗰 𝗦𝘂𝗿𝗴𝗲𝗼𝗻𝘀 (𝗝𝗔𝗔𝗢𝗦). In the review titled "Patient Comorbidities, Their Influence on Lumbar Spinal Fusion Surgery, and Recommendations to Reduce Unfavorable Outcomes," Butrico et al. delves into the effects of medical comorbidities on spinal fusion surgery outcomes to increase awareness of the associated surgical complications. This review 𝘂𝗻𝗱𝗲𝗿𝘀𝗰𝗼𝗿𝗲𝘀 𝘁𝗵𝗲 𝗻𝗲𝗲𝗱 𝗳𝗼𝗿 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝗱 𝗮𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀, 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗲𝗱𝘂𝗰𝗮𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗰𝗼𝗺𝗼𝗿𝗯𝗶𝗱𝗶𝘁𝗶𝗲𝘀 𝘁𝗼 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝘀𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀. Congratulations to the Kuros Medical Affairs team for this important contribution to the field! To read the full review, click here → https://lnkd.in/eDABK8WD #KurosBiosciences #MagnetOs #GrowBoneMagnetOs #NeedleGrip 

What factors are predictors of nonunion following midfoot arthrodesis? A recent retrospective study reported a multivariable logistical regression analysis comparing midfoot arthrodesis fusion outcomes and patient- and surgeon-related factors in 99 midfoot arthrodesis surgeries. A lack of adjuvant bone graft was one of four factors identified as an independent predictor of nonunion. To read the full article, click here → https://lnkd.in/eyvmk6nZ MagnetOsᵀᴹ bone graft is approved for use in midfoot arthrodesis surgery and promotes fusion even in complicated revision surgeries. To learn about MagnetOs use in foot and ankle arthrodesis, schedule a Meet the Expert → https://lnkd.in/e2swWaUX

A special thank you to Dr. Daniel Robinson of Indiana Spine Group and his team for allowing us to watch him perform an ALIF with percutaneous fixation using MagnetOsᵀᴹ Easypack Putty!   Pictured below is Dr. Robinson, Dan Buhler and Thomas Spoonmore, Ph.D., Scientific Affairs Manager at Kuros Biosciences.   Here’s to advancing surgical techniques and improving patient outcomes together! To learn about the recent 𝗶𝗻𝘃𝗲𝘀𝘁𝗶𝗴𝗮𝘁𝗼𝗿-𝗹𝗲𝗱, 𝗟𝗲𝘃𝗲𝗹 𝟭 𝗵𝘂𝗺𝗮𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗳𝗲𝗮𝘁𝘂𝗿𝗶𝗻𝗴 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀ᵀᴹ 𝗻𝗼𝘄 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝙎𝙥𝙞𝙣𝙚, click here → https://lnkd.in/e5K7XtsM   #KurosBiosciences #MagnetOs #Level1Data #GrowBoneMagnetOs #NeedleGrip

Happy Holidays from all of us at Kuros Biosciences! As we reflect on the past year, we're grateful for the opportunity to make a difference in patients' lives. Thank you to our incredible partners, colleagues, and community for your support and dedication. Cheers to a bright and healthy New Year filled with innovation, growth, and success.